膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The STAT3 (Luc) HEK293 Reporter Cell was engineered with the STAT3 response element driving luciferase expressing systems. The receptors expressing endogenously or transfected on this reporter cell were activated by corresponding ligands binding, transducing intracellular signals resulting in STAT3-RE mediated luminescence.
应用说明（Application）
• The discovery of activators or inhibitors by the STAT3 signaling bioactivity.
• Transfection host for some receptors concerning the STAT3 signaling pathway.
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Hygromycin (40 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Application
Inhibition of human IL-6 protein-induced reporter activity by anti-human IL-6 neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-6 protein (AcroBiosystems, Cat. No. IL6-H4218) with a final concentration of 2.5 ng/mL. The EC50 of anti-human IL-6 neutralizing antibody is approximately 0.04 μg/mL.
Protocol
Inhibition of human IL-6 protein-induced reporter activity by JAK inhibitor.
This reporter cell was incubated with serial dilutions of JAK inhibitors in the presence of human IL-6 protein with a final concentration of 2.5 ng/mL. The EC50 of JAK inhibitor (Baricitinib) was approximately 0.0108 μM.
Protocol
Signaling Bioassay
Response to human IL-6 protein (RLU).
The STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein (AcroBioystems, Cat. No. IL6-H4218). The EC50 was approximately 2.2 ng/mL.
Protocol
Response to human IL-6 protein (Fold).
The STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein (AcroBiosystems, Cat. No. IL6-H4218). The max induction fold was approximately 100.5.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein. Human IL-6 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 9-37.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes important for essential cellular processes including survival, proliferation, self-renewal, angiogenesis, and immune response. As an early tumor diagnostic marker, it is considered that constitutive STAT3 activation is a sufficient factor to cause malignant transformation and tumor development in model systems. The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
